# Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy

> **NCT01555632** · NA · WITHDRAWN · sponsor: **University of Nebraska**

## Conditions studied

- Recurrent Prostate Cancer
- Stage I Prostate Cancer
- Stage IIA Prostate Cancer
- Stage IIB Prostate Cancer
- Stage III Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** atorvastatin calcium
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01555632
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-03
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Other more favorable treatments are now available.
- **Last updated:** 2023-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01555632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01555632, "Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01555632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*